An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
Multifocal motor neuropathy (MMN) is a rare condition that causes muscle weakness, mainly in the hands and arms, due to nerve inflammation. This early-stage clinical trial is testing a study medicine called empasiprubart (ARGX-117) in adults who have MMN. In MMN, nerves can become swollen and irritated. In this study, doctors will use ultrasound imaging—a painless test using sound waves—to look at nerves in the neck and arm. They want to find out if empasiprubart can reduce this swelling after 24 weeks of treatment. The researchers will also check whether the medicine helps improve hand grip, finger dexterity, and general muscle strength. Throughout the trial, the medical team will closely monitor participant safety through routine health checks, blood tests, and heart tracings to understand if the drug is safe and well tolerated.
At a glance
What is this study about?
Multifocal motor neuropathy (MMN) is a rare, long-term condition affecting motor nerves, which are the nerves that tell your muscles to move. Over time, MMN leads to muscle weakness, twitching, and loss of movement, typically starting in the hands and lower arms. This can make simple, everyday tasks like doing up buttons, turning keys, or lifting objects increasingly difficult.
This Phase 1b trial is studying an experimental medicine called empasiprubart (also known as ARGX-117). In people with MMN, parts of the body's immune system mistakenly attack the outer layer of the nerves, causing them to become inflamed and enlarged. Researchers will use ultrasound scans—the same harmless technology used during pregnancy—to measure the thickness of nerves in the neck and arm to see if the medicine calms this swelling.
Because this is an 'open-label' study, all participants will receive empasiprubart; no one will receive a dummy drug (placebo). By tracking changes in nerve shape and measuring muscle strength over 24 weeks, doctors hope to discover whether empasiprubart could become a helpful future treatment option for people living with MMN.
Key takeaways
- This is a Phase 1b trial testing an experimental drug called empasiprubart for MMN.
- The study is open-label, meaning all participants receive the active treatment.
- Doctors will use painless ultrasound scans over 24 weeks to see if nerve swelling is reduced.
- Researchers will also measure hand grip, finger dexterity, and muscle strength.
- Taking part is entirely voluntary, and your health will be closely watched by specialists.
Who may be eligible?
This clinical trial is designed for adults aged 18 and older who have a confirmed medical diagnosis of multifocal motor neuropathy (MMN). Both men and women are eligible to join.
To take part, you will need to be able to attend scheduled clinic appointments and undergo non-invasive nerve ultrasound scans. You should also be able to complete basic strength and movement tests with your hands and arms.
People with certain other neurological conditions or significant medical issues might not be able to join for safety reasons. The trial doctor will carefully review your full medical history and current medications to confirm whether taking part is safe and suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You have a formal diagnosis of multifocal motor neuropathy (MMN).
- You are willing to travel to a trial centre for regular appointments over 24 weeks.
- You are comfortable having ultrasound scans and routine blood tests.
- You are able to carry out simple hand grip and movement tests.
What does participation involve?
If you take part, you will receive the study medicine, empasiprubart, over a 24-week period. You will need to attend regular clinic appointments at a hospital study centre. During these visits, doctors will perform painless ultrasound scans on your arms and neck to measure your nerves. You will also take simple physical tests, such as squeezing a hand-grip device and placing small pegs into holes on a board, to measure your strength and finger control. The study team will track your overall health using regular blood samples, urine tests, blood pressure checks, and heart traces (ECGs).
Potential risks and benefits
Locations (12)
- —UnverifiedSlovenia
- —UnverifiedLatvia
- —UnverifiedDenmark
- —UnverifiedGermany
- —UnverifiedBelgium
- —UnverifiedNorway
- —UnverifiedSpain
- —UnverifiedPoland
- —UnverifiedLithuania
- —UnverifiedItaly
- —UnverifiedFrance
- —UnverifiedNetherlands
Common questions
What does an open-label study mean?
An open-label study means that both you and your study doctors know which treatment you are getting. Everyone in this trial receives the active study medicine, and there is no placebo (dummy treatment).
Does the nerve ultrasound hurt?
No, it is completely painless. A small amount of cool gel is placed on your skin, and a handheld probe is gently moved across your arm and neck to take pictures of your nerves.
Will I need to stop my current MMN treatments?
You should never stop or change your regular medicines on your own. The study doctors will talk to you about your current treatments and explain how they work alongside the trial rules.
How long will I be involved in the study?
The main treatment and assessment period lasts for 24 weeks, though you may also have initial screening visits before starting and a follow-up check after the treatment finishes.
What if I decide I no longer want to participate?
You can leave the study at any time, for any reason. You do not have to give an explanation, and leaving will not harm your relationship with your healthcare team or change your normal treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.